NICOLAUS COPERNICUS UNIVERSITY IN TORUŃ

Journal of Education, Health and Sport. eISSN 2391-8306.

Journal Home Page
https://apcz.umk.pl/JEHS/index

WOJCIESZAK, Maja, GĘBORYS, Anna, KANIA, Joanna, MAZIARCZYK, Alicja, LAMBACH, Jakub, KUTNIK, Kacper, WOŹNICA, Weronika, DĄBROWSKA, Julia, BIAŁOGŁOWSKI, Michał, and MAZUREK, Katarzyna. Postpartum Depression: From Molecular Mechanisms to Clinical Management – A State-of-the-Art Review for the Obstetrician. Journal of Education, Health and Sport. 2026;90:69957. eISSN 2391-8306. https://doi.org/10.12775/JEHS.2026.90.69957

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 18.03.2026. Revised: 24.03.2026. Accepted: 10.04.2026. Published: 12.04.2026.

Postpartum Depression: From Molecular Mechanisms to Clinical Management – A State-of-the-Art Review for the Obstetrician

Maja Wojcieszak
Medical University of Lublin, Poland
ORCID https://orcid.org/0009-0005-7384-8605
majawojcieszak13@gmail.com

Anna Gęborys
Medical University of Lublin, Poland
ORCID https://orcid.org/0009-0009-1062-3790
ageborys23@gmail.com

Joanna Kania
University Clinical Hospital No. 1 in Lublin
ORCID https://orcid.org/0009-0005-6156-6192
1joanna.kania1@gmail.com

Alicja Maziarczyk
1University Clinical Hospital No. 4 in Lublin
ORCID http://orcid.org/0009-0001-6634-4215
Alicja.maziarczyk00@gmail.com

Jakub Lambach
Medical University of Lublin, Poland
ORCID http://orcid.org/0009-0003-6928-3037
Klambach97@gmail.com

Kacper Kutnik
Medical University of Lublin, Poland
ORCID https://orcid.org/0009-0000-5091-1302
kkutnik@icloud.com

Weronika Woźnica
Medical University of Lublin, Poland
ORCID https://orcid.org/0009-0007-1549-7290
weronikawoznica@onet.pl

Julia Dąbrowska
Medical University of Lublin, Poland
ORCID https://orcid.org/0009-0000-5273-5031
julia_dabrowska001@wp.pl

Michał Białogłowski
Casimir Pulaski Radom University, Poland
ORCID https://orcid.org/0009-0002-8664-0545
mibia323@gmail.com

Katarzyna Mazurek
Stefan Cardinal Wyszynski Regional Specialized Hospital in Lublin, Poland
ORCID https://orcid.org/0009-0001-4433-9001
kasiaa.mazurek@gmail.com

Corresponding Author
Maja Wojcieszak, majawojcieszak13@gmail.com

ABSTRACT

Background. Postpartum depression (PPD) is a common childbirth complication, affecting an estimated 17.2% of women worldwide. Unlike the short-lived "baby blues," PPD is a unique neurobiological illness defined by an inability to adapt synaptically to reproductive hormone withdrawal. It is the most common cause of maternal suicide, and the offspring of PPD mothers also suffer long-lasting cognitive and emotional impairments.

Aim. Our objective was to review the pathophysiology of PPD (with special emphasis on the GABAergic and immuno-inflammatory hypotheses), screening procedures and to outline a "stepped-care" management algorithm, including new neuroactive steroids.

Material and Methods. A systematic literature search was conducted using PubMed/MEDLINE, Embase, and Cochrane databases (Jan 2010 – Dec 2024). We prioritized meta-analyses, randomized controlled trials (RCTs), and guidelines from major obstetric societies (ACOG, RCOG).

Results. There is evidence for current hypothesis of rapid withdrawal of allopregnanolone as trigger of the development of symptoms that do not initiate the adequate GABA-A receptor reorganization in vulnerable women. Other mechanisms include HPA axis dysregulation and inflammation-induced tryptophan depletion. The gold standard for screening remains the Edinburgh Postnatal Depression Scale (EPDS) Sensitivity: 86%). Pharmacologic treatment has significantly progressed: Sertraline remains the first-line SSRI due to safety in lactation, but the FDA approval of Zuranolone (2023) provides a mechanism-specific, rapid-acting therapeutic option addressing the underlying hormonal dysregulation.

Conclusions. Obstetricians are the primary gatekeepers for maternal mental health. Preparation of obstetricians to identify women at higher risk and to treat with pharmacotherapy is an essential part of contemporary obstetric practice.

Keywords: Postpartum depression, allopregnanolone, neuroinflammation, GABA-A receptor, zuranolone, sertraline

1.Introduction

The transformation to mothers is a physically and mentally challenging process. Cultural narratives highlight delight, but for almost one in five women it is an incapacitating mood illness. The fifth edition of the Diagnostic and Statictical Manual of Mental Disorders, Text Revision (DSM-5-TR) classifies PPD as a major depressive episode with peripartum onset; however, the period of clinical risk continues through the first postpartum year [1].

1.1 Epidemiology and Economic Burden

According to recent meta-analyses, the global pooled prevalence of PPD is 17.2%, with high heterogeneity across SES [2]. The societal costs of untreated perinatal mood and anxiety disorders (PMADs) in the US alone are calculated to be $14.2B, and growing [4]. This cost is due not to cost of treatment but to the downstream consequences of lost maternal productivity, preterm birth complications and long-term child developmental services [3].

1.2. The Clinical Imperative

PPD is a fatal disease. Suicide is a major cause of maternal death in high income countries, representing up to 20% of deaths during the postpartum period.1 Alarmingly, retrospective studies show that a substantial number of women who died by suicide had multiple contacts with the healthcare system in the perinatal period and were not screened for psychiatric distress [4]. This underscores the importance of the obstetrician-gynecologist, who is frequently the only doctor a woman meets with in this vulnerable “fourth trimester".

2. Material and Methods

2.1. Search Strategy

A narrative review was performed using the following term databases: PubMed, PsycINFO, and Scopus. Keywords included: ("Depression, Postpartum" OR "Perinatal Depression") AND ("Pathophysiology" OR "GABA" OR "Inflammation") AND ("Screening" OR "EPDS") AND ("Pharmacotherapy" OR "Zuranolone" OR "Sertraline").

2.2. Criteria for (in)exclusion

Inclusion: systematic reviews; RCTs on pharmacotherapy; ACOG/NICE guidelines published in the English language between 2010 and 2024.

Exclusion: Work addressing exclusively postpartum psychosis (unless pertinent to differential diagnosis) or non-peer-reviewed opinion pieces.

3. Differential Diagnosis: The Spectrum of Perinatal Mood Disorders

Accurate diagnosis is the prerequisite for safety. The clinician must differentiate PPD from "Baby Blues" (benign) and Postpartum Psychosis (emergency).

Feature	**Postpartum Blues**	**Postpartum Depression (PPD)**	**Postpartum Psychosis**
Incidence	50–80%	10–20%	0.1–0.2%
Onset	Days 3–5 postpartum	4 weeks to 12 months	Rapid (Weeks 1–4)
Duration	< 2 weeks	Months to Years (if untreated)	Variable
Symptoms	Tearfulness, irritability, insomnia	Anhedonia, guilt, suicidality, psychomotor agitation	Delusions, hallucinations, confusion, mania
Treatment	Reassurance & Rest	Psychotherapy / SSRIs / Neurosteroids	**Emergency Hospitalization**

3.1. Bipolar Disorder Diagnostic Pitfalls

Not recognizing Bipolar Disorder is a life-threatening diagnostic mistake. As many as 22% of women who screen positive for depression are in fact suffering from Bipolar II disorder. The start of SSRI monotherapy in these patients may lead to a manic or mixed episode, which in turn may increase suicide risk. **Clinical Pearl:** Prior to prescribing antidepressants every patient with elevated EPDS scores be screened for a history of mania with the MDQ [5].

4. Pathophysiology: A "Perfect Storm" of Biology

PPD is not just a normal response to the stress of parenting; it is a discrete biological phenotype.

4.1. The Neurosteroid Withdrawal Hypothesis (GABAergic Dysfunction)

This is the active mechanism of explaining the timing unique to PPD.

- **Pregnancy:** Progesterone levels increase significantly along with that of its metabolite, allopregnanolone. Allopregnanolone is a powerful positive allosteric modulator (PAM) of the GABA-A receptor (the brain's "brake"). In order to avoid sedation, these receptors (specifically the delta-subunit) are downregulated in the maternal brain [6].
- **Parturition:** After placental delivery, progesterone/allopregnanolone levels crash by 99% within 48 hours.
- **The Mismatch:** GABA-A receptors in healthy women rapidly reorganize to recover sensitivity. In PPD, this plasticity is absent. The receptors continue to be desensitized in spite of low levels of neurosteroids, resulting in neuronal hyperexcitation, anxiety and sleep deprivation. This mechanism is targeted by the novel agents brexanolone and zuranolone [7].

4.2. Immuno-Inflammatory Pathways and the Kynurenine Pathway

Pregnancy is an immune-tolerant state, but the postpartum period involves a rebound of the immune system.

- **Cytokine Storm:** Women with PPD exhibit elevated levels of IL-6, TNF-alfa, and CRP.
- **The Tryptophan Steal:** Pro-inflammatory cytokines activate the enzyme **indoleamine 2,3-dioxygenase (IDO)**. IDO degrades tryptophan (the precursor of serotonin) into **kynurenine**. This leads to two consequences:

1. **Serotonin Depletion:** Less tryptophan is available for serotonin synthesis.
2. **Neurotoxicity:** Kynurenine metabolites are neurotoxic to the hippocampus, potentially causing the cognitive fog and memory deficits seen in PPD [8, 9].

4.3 The HPA AXIS and Cortisol

During pregnancy, placental CRH induces hypercortisolism. HPA axis suppression occurs postpartum. In PPD this suppression is extended in time. Salivary cortisol studies report a "blunted Cortisol Awakening Response (CAR)", suggesting a tuned, unreactive stress system which might be unable to handle the stress of childcaring [10].

4.4 Epigenetics

Emerging evidence shows alterations of DNA methylation in TTC9B and HP1BP3, both of which are modulated by estrogen. These epigenetic marks, which are detectable in blood, could potentially be used as biomarkers for the prediction of PPD risk as early as the first trimester [11].

5. Detailed Risk Stratification

Risk assessment should begin at the first prenatal visit.

5.1. Historical Factors (The Strongest Predictors)

- **Antenatal Depression:** OR = 5.0. The strongest predictor of PPD is depression *during* pregnancy [12].
- **History of PMDD:** Women with Premenstrual Dysphoric Disorder have a demonstrated sensitivity to hormonal fluctuations ("hormone sensitivity trait").
- **Previous PPD:** Recurrence risk is approximately 25-40%.

5.2. Obstetric and Birth Trauma

- **Traumatic Delivery:** Emergency C-sections, instrumental delivery, or perceived lack of control during labor are strongly linked to PPD and Postpartum PTSD. Often, the *subjective* experience of the birth matters more than the objective medical outcome [13].
- **Breastfeeding Difficulty:** The relationship is bidirectional. Pain, latch issues, and low supply trigger feelings of failure. Conversely, depression can inhibit the let-down reflex via catecholamine release [14].

5.3. Psychosocial Determinants

- **Intimate Partner Violence (IPV):** A critical red flag.
- **Low Social Support:** Isolation is a more potent risk factor than financial poverty alone [15].

6. Screening Protocols

6.1 The Edinburgh Postnatal Depression Scale (EPDS)

The EPDS is considered the standard. It is not a classic depression screen such the PHQ-9, it does not include somatic symptoms (fatigue, change of sleep) that are considered normal for new mothers, and that would artificially inflate false-positives.

Validity: Sensitivity 86%, Specificity 78 % [16].

Scoring:

- **>10:** Suggests minor/major depression.
- **>13:** Highly likely major depression.
- **Item 10 (Suicidality):** "The thought of harming myself has occurred to me." **Any** score other than "Never" requires immediate suicide risk assessment.

6.2. When to Screen?

ACOG recommends a hybrid model:

1. **Antepartum:** At least once (24-28 weeks).
2. **Postpartum:** At the routine puerperal visit (4-6 weeks).
3. **Pediatrics:** The American Academy of Pediatrics (AAP) recommends screening mothers at the 1, 2, and 4-month well-child visits [17].

7. Management: The "Stepped Care" Algorithm

Treatment must be individualized based on severity (EPDS score) and functional impairment.

7.1. Step 1: Mild Depression (EPDS 10-12)

- **Strategy:** Non-pharmacological support.
- **Psychoeducation & Sleep Hygiene:** Enforcing a 4-hour unprotected sleep window for the mother (partner gives a bottle) can be curative. Sleep deprivation mimics depression.
- **Peer Support:** Connection with other mothers to reduce isolation.

7.2. Step 2: Moderate Depression (EPDS 13-19)

- Psychotherapy CBT and IPT are first-line.

- Pharmacologic therapy (SSRIs) Therapy is not feasible or sufficient.

    - Sertraline: The Gold Standard. Because of its low lipid solubility and high degree of protein binding, the excretion of citalopram into the breast milk is very low. Infant serum levels are usually undetectable [18]. Start 25-50 mg.

    - Paroxetine: Breastfeeding — safe to use but avoid in women who are likely to become pregnant again in the near future due to risk of teratogenicity.

    - Fluoxetine: Caution. Because of long half-life (active metabolite 4-16 d) it may accumulate in infant and induce colic and jitteriness. Generally avoided for new

starts in lactation, though often continued if the mother was stable on it during pregnancy [18].

7.3. Step 3: Severe/Resistant Depression (EPDS >20)

- **Referral:** Psychiatry consultation is mandatory.
- **Novel Neurosteroids (The New Paradigm):**
    - **Zuranolone (Zurzuvae):** FDA-approved (2023). An oral neuroactive steroid.
        - *Protocol:* 50mg daily for 14 days.
        - *Data:* The SKYLARK trial showed rapid reduction in depressive symptoms by Day 3, with sustained remission at Day 45. It works by rapidly restoring the GABA-A receptor tone/function [19].
    - **Brexanolone (Zulresso):** FDA-approved (2019).
        - *Protocol:* 60-hour continuous IV infusion. Requires inpatient monitoring due to risk of sedation. Highly effective for severe, treatment-resistant cases [20]

8. Prevention Strategies

Can PPD be avoided?

- **Prophylactic Antidepressants:** For women with a history of severe PPD, beginning Sertraline immediately postpartum (Day 0) is associated with substantially lower rates of recurrence compared to placebo [21].
- **Dietary Supplementation:** Preliminary data indicate that supplementation with Omega-3 fatty acids and Vitamin D in pregnancy might provide a mild protective effect [22].

9. Barriers to Care and Future Directions

9.1. The Referral Gap

Despite screening, only ~20% of positive cases receive treatment. This "referral gap" is driven by a shortage of perinatal psychiatrists. Integrated care models (e.g., MCPAP for Moms), where obstetricians have telephone access to psychiatrists, are proving effective in bridging this divide [23].

9.2. Biomarkers

The future of PPD management lies in objective testing. Panels measuring oxytocin, BDNF, and inflammatory cytokines are currently in validation trials to predict risk before symptoms appear.

10. Conclusions

Postpartum depression is a complex neuroendocrine disorder, not a character flaw. The obstetrician's role has evolved from purely somatic care to a holistic model integrating mental health.

1. **Biological Reality:** PPD is driven by GABAergic dysregulation and inflammation.
2. **Screening:** Universal EPDS screening is non-negotiable in modern practice.
3. **Treatment Competency:** Obstetricians must be comfortable prescribing Sertraline and recognizing the indication for Zuranolone. Treating the mother is the single most effective intervention for the health of the child.

Author's Contribution

Conceptualization - Maja Wojcieszak
Methodology - Maja Wojcieszak, Anna Gęborys
Software - Maja Wojcieszak
Check - Maja Wojcieszak, Joanna Kania
Formal analysis - Maja Wojcieszak, Kacper Kutnik
Investigation - Maja Wojcieszak, Alicja Maziarczyk
Resources - Maja Wojcieszak, Michał Białogłowski

Data curation - Maja Wojcieszak
Writing - rough preparation - Maja Wojcieszak, Jakub Lambach, Anna Gęborys, Joanna Kania, Kacper Kutnik, Alicja Maziarczyk
Writing - review and editing - Maja Wojcieszak, Kasia Mazurek, Michał Białogłowski, Julia Dąbrowska, Weronika Woźnica
Visualization - Maja Wojcieszak, Julia Dąbrowska
Supervision - Maja Wojcieszak, Weronika Woźnica
Project administration - Maja Wojcieszak
All authors have read and agreed with the published version of the manuscript.

Funding Statement
The study did not receive special funding

Institutional Review Board Statement
Not applicable.

Informed Consent Statement
Not applicable.

Data Availability Statement
Not applicable.

Acknowledgments
Not applicable.

Conflict of Interest Statement
There are no conflicts of interests in the study

References

[1]American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)*. 5th ed. Washington, DC: APA; 2022. https://doi.org/10.1176/appi.books.9780890425787

[2]Wang Z, Liu J, Shuai H, et al. Mapping global prevalence of depression among postpartum women. *Transl Psychiatry*. 2021;11(1):543. https://doi.org/10.1038/s41398-021-01663-6

[3]Luca DL, Garlow N, Staatz C, et al. Societal Costs of Untreated Perinatal Mood and Anxiety Disorders in the United States. *Mathematica Policy Research*. 2019. https://www.mathematica.org/publications/societal-costs-of-untreated-perinatal-mood-and-anxiety-disorders-in-the-united-states

[4]Trost SL, Beauregard J, Njie F, et al. Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees in 36 US States. *CDC*. 2022. https://www.cdc.gov/maternal-mortality/php/data-research/mmrc-2017-2019.htm l

[5]Wisner KL, Sit DK, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. *JAMA Psychiatry*. 2013;70(5):490-498. https://doi.org/10.1001/jamapsychiatry.2013.87

[6]Maguire J. Neuroactive steroids and GABAergic involvement in the neurobiology of postpartum depression. *Front Cell Neurosci*. 2019;13:23. https://doi.org/10.3389/fncel.2019.00023

[7]Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. *Am J Psychiatry*. 2023;180(9):668-675. https://doi.org/10.1176/appi.ajp.20220785

[8]Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(3):676-692. https://doi.org/10.1016/j.pnpbp.2010.05.008

[9]Osborne LM, Monk C. Perinatal depression—the fourth inflammatory morbidity of pregnancy? *Psychoneuroendocrinology*. 2013;38(10):1929-1952. https://doi.org/10.1016/j.psyneuen.2013.03.019

[10]Iliadis SI, Koulouris P, Gingnell M, et al. Personality and salivary cortisol in women with symptoms of postpartum depression. *Arch Womens Ment Health*. 2015;18(6):815-823. https://doi.org/10.1007/s00737-015-0524-7

[11]Guintivano J, Arad M, Gould TD, et al. Antenatal prediction of postpartum depression with blood DNA methylation biomarkers. Mol Psychiatry. 2014;19(5):560-567. https://doi.org/10.1038/mp.2013.62

[12]Beck CT. Predictors of postpartum depression: an update. *Nurs Res*. 2001;50(5):275-285. https://doi.org/10.1097/00006199-200109000-00004

[13]Dekel S, Stuebe C, Dishy G. Childbirth Induced Posttraumatic Stress Syndrome: A Systematic Review of Prevalence and Risk Factors. *Front Psychol*. 2017;8:560. **https://doi.org/10.3389/fpsyg.2017.00560**

[14]Dias CC, Figueiredo B. Breastfeeding and depression: a systematic review of the literature. *J Affect Disord*. 2015;171:142-154. https://doi.org/10.1016/j.jad.2014.09.022

[15]Yim IS, Tanner Stapleton LR, Guardino CM, et al. Biological and psychosocial predictors of postpartum depression: systematic review and call for integration. *Annu Rev Clin Psychol*. 2015;11:99-137. https://doi.org/10.1146/annurev-clinpsy-101414-020426

[16]Levis B, Benedetti A, Thombs BD. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression. *BMJ*. 2020;371:m4022. https://doi.org/10.1136/bmj.m4022

[17]Earls MF; AAP Committee on Psychosocial Aspects. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. *Pediatrics*. 2010;126(5):1032-1039. https://doi.org/10.1542/peds.2010-2548

[18]Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of Antidepressants in Breastfeeding Mothers. *Breastfeed Med*. 2015;10(6):290-299. https://doi.org/10.1089/bfm.2015.29002.nks

[19]Deligiannidis KM, Lasser R, Gunduz-Bruce H, et al. Zuranolone for the Treatment of Postpartum Depression: A Randomized Clinical Trial. *JAMA Psychiatry*. 2021;78(9):951-959. https://doi.org/10.1001/jamapsychiatry.2021.1559

[20]Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet*. 2018;392(10152):1058-1070. https://doi.org/10.1016/S0140-6736(18)31551-4

[21]Wisner KL, Perel JM, Peindl KS, et al. Prevention of postpartum depression: a pilot randomized clinical trial. *Am J Psychiatry*. 2004;161(7):1290-1292. https://doi.org/10.1176/appi.ajp.161.7.1290

[22]Sparling TM, Henschke N, Nesbitt RC, Gabrysch S. The role of diet and nutritional supplementation in perinatal depression: a systematic review. *Matern Child Nutr*. 2017;13(1). https://doi.org/10.1111/mcn.12235

[23]Byatt N, Straus J, Stopa A, et al. Massachusetts Child Psychiatry Access Program for Moms: Utilization and Quality Assessment. *Obstet Gynecol*. 2018;132(2):345-353. https://doi.org/10.1097/AOG.0000000000002733

[24]Howard LM, Khalifeh H. Perinatal mental health: a review of progress and challenges. *World Psychiatry*. 2020;19(3):313-327. https://doi.org/10.1002/wps.20769

[25]Putnam KT, Wilcox M, Robertson-Blackmore E, et al. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. *Lancet Psychiatry*. 2017;4(6):477-485. https://doi.org/10.1016/S2215-0366(17)30136-0

[26]Silverman ME, Reichenberg A, Savitz DA, et al. The risk factors for postpartum depression: A population-based study. *Depress Anxiety*. 2017;34(2):178-187. https://doi.org/10.1002/da.22597

[27]Battle CL, Zlotnick C, Miller IW, et al. Clinical characteristics of perinatal bipolar disorder. *Bipolar Disord*. 2014. https://doi.org/10.1111/bdi.12151

[28]Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. *Front Neuroendocrinol*. 2019;52:165-180. https://doi.org/10.1016/j.yfrne.2018.12.001

[29]Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet*. 2017. https://doi.org/10.1016/S0140-6736(17)31264-6

[30]ACOG Committee Opinion No. 757: Screening for Perinatal Depression. *Obstet Gynecol*. 2018. https://doi.org/10.1097/AOG.0000000000002927

[31]O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. *Annu Rev Clin Psychol*. 2013;9:379-407. https://doi.org/10.1146/annurev-clinpsy-050212-185612

[32]Stewart DE, Vigod S. Postpartum Depression. *N Engl J Med*. 2016;375(22):2177-2186. https://doi.org/10.1056/NEJMcp1607649

[33]Shorey S, Chee CYI, Ng ED, et al. Prevalence and incidence of postpartum depression among healthy mothers: A systematic review and meta-analysis. *J Psychiatr Res*. 2018;104:235-248. https://doi.org/10.1016/j.jpsychires.2018.08.001